FDA Issues 'Safety Communication' on Fenofibrate

FDA Issues 'Safety Communication' on Fenofibrate: The agency has updated the prescribing information for the cholesterol-lowering agent, stating that it may not lower the risk of major cardiovascular events, and is requesting Abbott to conduct another study.
Heartwire